Canaccord analyst Whitney Ijem lowered the firm’s price target on Tenaya Therapeutics to $17 from $18 and keeps a Buy rating on the shares. The firm said its Q2 report was uneventful as pipeline progress remains on track and they updated their model to reflect its 2Q23 earnings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNYA: